Our latest Annual Report, detailing progress throughout 2019-2020, is now available online.
Dr. Judith Campisi is one of 30 leading researchers who act as advisors to SRF.
Dr. Aubrey de Grey and Jim O’Neill drive SRF into its second decade of innovative research.
We fund innovative research at universities across the world, at our own Research Center in Mountain View, CA, and through investments in early stage companies.
Our research emphasizes the application of regenerative medicine to age-related disease, with the intent of repairing underlying damage to the body’s tissues, cells, and molecules. Our goal is to help build the industry that will cure the diseases of aging.
Our current outreach efforts include the Undoing Aging conference series in Berlin, Germany, summits, speaking engagements, and general advocacy. We strive to inform world policy-makers, health professionals, and the general public about our damage-repair approach to treating, and curing, age-related disease.
Finally, SRF engages in educational work through our student program, SRF Education. SRF Education operates an undergraduate summer internship program, as well as a 10-month post-baccalaureate program, both of which place students and new researchers at the SRF Research Center and world-class institutions. The programs provide participants with guidance, mentorship, and materials grants for SENS-related research projects.
Dr. Aubrey de Grey and Jim O’Neill drive SRF into its second decade of innovative research.
Comprised of forward-thinking, mission-driven individuals, the Board continues to grow SRF into a global powerhouse for change.
World renowned experts from all areas of rejuvenation biotechnology act as SRF’s scientific advisors on the SENS approach to aging.
SRF staff is comprised of mission-driven individuals who work tirelessly towards our goals of ending age-related disease.
No. Rejuvenation biotechnologies by definition would work by restoring healthy structure and function to the body.
Clearly, the degenerative aging process causes a great deal of suffering within the scope of the lives we live now, and clearly we are not alone in making this observation; otherwise the entire field of geriatric medicine would not exist.
Therefore, even when discussing longevity as an incidental effect of SENS-type treatments, it should go without saying that our priority, and the true triumph of rejuvenation biotech, will be that of increasing the human healthspan – i.e., the proportion of life spent feeling and functioning well, as opposed to the proportion spent struggling to endure pain, disease, dementia, and so on.
Keep up to date with SRF research, activities, and finances by reading our Annual Report – published each spring.
Annual 990 information is available for the general public to review.
Use this form to contact SENS Research Foundation.
Before making an enquiry, we suggest you read through our FAQ page to see whether your question is addressed there.
SENS Research Foundation is aggressively pursing the most basic, fundamental research in the new science of rejuvenation biotechnology. SENS Research Foundation does not currently manage clinical trials, and none of our research programs are able to make use of human subjects.
We also encourage you to visit our Donate page if you wish to invest in the future of rejuvenation biotechnologies.
Sign up to stay informed about the latest news and opportunities with SRF!
Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.
© 2020 SENS Research Foundation – ALL RIGHTS RESERVED